Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245781 | 0.83 | AVPR1A (0.50) | AVPR1A | |
| SCHEMBL4206840 | 0.80 | SIGMAR1 (0.80) | SIGMAR1 | |
| SCHEMBL2517838 | 0.80 | SIGMAR1 (0.54) | SIGMAR1AVPR1A | |
| Hydrochloric Acid SCHEMBL2882074 | 0.79 | SIGMAR1 (0.78) | SIGMAR1 | |
| SCHEMBL4075995 | 0.78 | SIGMAR1 (0.51) | SIGMAR1 | |
| SCHEMBL2514268 | 0.76 | SIGMAR1 (0.59) | SIGMAR1 | |
| SCHEMBL2514316 | 0.76 | SIGMAR1 (0.67) | SIGMAR1 | |
| SCHEMBL2360705 | 0.75 | SIGMAR1 (0.73) | SIGMAR1 | |
| SCHEMBL16836026 | 0.75 | AVPR1A (0.52) | SIGMAR1AVPR1A | |
| SCHEMBL2360267 | 0.75 | SIGMAR1 (1.00) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218381-B1 | SPIRO-THIAZOLONES | HOFFMANN LA ROCHE (CH) | 2019-01-23 | — | — | EP | disclosed |
| EP-3218381-B1 | SPIRO-THIAZOLONES | HOFFMANN LA ROCHE (CH) | 2019-01-23 | — | — | EP | disclosed |
| US-10092551-B2 | Spiro-thiazolones | HOFFMANN-LAROCHE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3218381-A1 | SPIRO-THIAZOLONES | F. Hoffmann-La Roche AG (CH) | 2017-09-20 | — | — | EP | disclosed |
| US-20170246153-A1 | SPIRO-THIAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246153-A1 | SPIRO-THIAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246153-A1 | SPIRO-THIAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-08-31 | — | — | US | disclosed |
| WO-2016075181-A1 | SPIRO-THIAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016075181-A1 | SPIRO-THIAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-19 | — | — | WO | disclosed |
| US-8044202-B2 | e.g.1'-[(6-chloro-1H-indol-3-yl)carbonyl]-7H-spiro[pentane[3,4-b]pyridine-5,4'-piperidine]; vasopressin V1a receptor antagonist; antidepressant and anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20080281103-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080281103-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-11-13 | — | — | US | disclosed |
| WO-2008080844-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080844-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161333-A1 | AZASPIRO DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161333-A1 | AZASPIRO DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161333-A1 | AZASPIRO DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | US | disclosed |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | US | disclosed |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10092551-B2 | Spiro-thiazolones | AVPR1A, AVPR2, AVPR1B | SIGMAR1 113/4885AVPR1A 1/4885 |
| US-20080281103-A1 | AZASPIRO DERIVATIVES | AVPR1A, HTR5A, HTR1A | SIGMAR1 78/4885AVPR1A 1/4885 |
| US-20080161332-A1 | AZASPIRO DERIVATIVES | AVPR1A, HTR5A, HTR1A | SIGMAR1 78/4885AVPR1A 1/4885 |
| US-20080161333-A1 | AZASPIRO DERIVATIVES | AVPR1A, HTR5A, HTR1A | SIGMAR1 78/4885AVPR1A 1/4885 |
| US-20170246153-A1 | SPIRO-THIAZOLONES | AVPR1A, AVPR2, AVPR1B | SIGMAR1 113/4885AVPR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.